Vir Biotechnology Stock News

Glaxo (GSK) and Vir Biotechnology announce promising pre-clinical data from the study of their antibody candidate, sotrovimab, against mutations found in the Omicron variant.

London, Dec 3 (IANS) British drugmaker GlaxoSmithKline has claimed that early laboratory tests show that its antibody drug against Covid-19 is effective against the new super mutant Omicron variant. GSK developed Sotrovimab, with US partner Vir Biotechnology, a monoclonal antibody based on the natural antibodies humans already make. In clinical trials, sotrovimab was shown to [] The post GSKs early data shows Covid antibody drug effective against Omicron appeared first on Buziness Bytes .

Related Stocks: VIR ,

A Covid-19 antibody treatment developed by GlaxoSmithKline and Vir Biotechnology was effective against the Omicron variant in early laboratory studies.

Developed by GSK and Vir Biotechnology, sotrovimab is a single monoclonal antibody and the drug works by binding to the spike protein on the outside of the Covid-19 virus, preventing the virus from attaching to and entering human cells, so that it cannot replicate in the body.

Futures Rebound Fizzles On Slowing iPhone Demand, Omicron Fears U.S. index futures regained some ground alongside Asian markets while European stocks slumped to session lows in a delayed response to yesterday''s late Omicron-driven US selloff, as markets remained volatile following the biggest two-day plunge in more than a year, spurred by concern about the omicron coronavirus variant and Federal Reserve tightening. Investors await data for unemployment claims, as well as earnings from companies including Dollar General and Kroger. Tech is the weakest sector, dropping in sympathy after Apple warned its suppliers of slowing iPhone demand. Nasdaq futures pared earlier gains of up to 0.8% to trade down 0.1% while S&P futures are only 0.2% higher after rising as much as 0.9%. While the knee-jerk reaction of stock investors may continue to be to take profits before the end of the year, there is plenty of liquidity available to drive stock prices higher as dip-buyers enter the market , Ed Yardeni wrote in a note.

In last trading session, Vir Biotechnology Inc. (NASDAQ:VIR) saw 3.52 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $46.97 trading at -$0.45 or -0.95% at ring of the bell on the day assigns it a market valuation of $5.95B. That closing price of VIRs stock is After A 50.40% Jump This Year Is Vir Biotechnology Inc. (NASDAQ:VIR) A Better Buy Than Others? Read More »

LONDON: British regulators on Thursday approved a GlaxoSmithKline drug to treat those at high risk of developing severe Covid-19 symptoms, with the manufacturer saying it appears effective against the new Omicron variant. The antibody treatment, sotrovimab, "was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease," said the Medicines and Healthcare products Regulatory Agency (MHRA). Preclinical data showed that the drug "retains activity against key mutations of the new Omicron SARS-CoV-2 variant," GlaxoSmithKline (GSK) said in a statement. First known UAE case of Omicron variant detected in fully vaccinated traveller "To date, sotrovimab has demonstrated ongoing activity against all tested variants of concern and interest defined by the World Health Organization (WHO)," it added. Testing is ongoing "to confirm the neutralising activity of sotrovimab against the combination of all the Omicron mutations with the intent to provide an update by the end of 2021." A single dose of the drug was found to reduce the risk of hospitalisation and death by 79 percent in high-risk adults with symptomatic COVID-19 infection, according to the MHRA.

The stock price of Vir Biotechnology Inc (NASDAQ: VIR) increased by over 20% pre-market today. This is why it happened.

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced an update to bioRxiv, a preprint server, with preclinical data for sotrovimab, COVID-19 targeting monoclonal

Could biotech stocks be top buys as the world battles a new Covid-19 variant?

Vir Biotechnology, Inc. (NASDAQ:VIR) shares were up 10.7% during trading on Monday . The company traded as high as $41.69 and last traded at $39.84. Approximately 19,813 shares were traded during trading, a decline of 98% from the average daily volume of 1,157,827 shares. The stock had previously closed at $36.00. A number of analysts []

Latest Ratings for VIR Date Firm Action From To Nov 2021 HC Wainwright … Full story available on Benzinga.com

Vir Biotechnology has a Covid-19 treatment that its CEO says will do well against new variants. Amid uncertainty, VIR stock is climbing.

The shares of Vir Biotechnology Inc (NASDAQ: VIR) have received a price target of $200 from H.C. Wainwright.